相似文献
1
Recent Advances in Dysuricemia: Toward Optimal Serum Urate Level.
Biomedicines. 2024 May 15;12(5):1094. doi: 10.3390/biomedicines12051094.
2
Dysuricemia.
Biomedicines. 2023 Nov 28;11(12):3169. doi: 10.3390/biomedicines11123169.
3
Dysuricemia-A New Concept Encompassing Hyperuricemia and Hypouricemia.
Biomedicines. 2023 Apr 23;11(5):1255. doi: 10.3390/biomedicines11051255.
4
Renal urate handling: clinical relevance of recent advances.
Curr Rheumatol Rep. 2005 Jun;7(3):227-34. doi: 10.1007/s11926-996-0044-0.
5
Hypouricemia and Urate Transporters.
Biomedicines. 2022 Mar 11;10(3):652. doi: 10.3390/biomedicines10030652.
6
Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
Expert Opin Pharmacother. 2021 Aug;22(11):1397-1406. doi: 10.1080/14656566.2021.1918102. Epub 2021 Apr 30.
7
A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Arthritis Rheum. 2011 Dec;63(12):4002-6. doi: 10.1002/art.30649.
8
Recent approaches to gout drug discovery: an update.
Expert Opin Drug Discov. 2020 Aug;15(8):943-954. doi: 10.1080/17460441.2020.1755251. Epub 2020 Apr 24.
9
Genetic disorders resulting in hyper- or hypouricemia.
Adv Chronic Kidney Dis. 2012 Nov;19(6):398-403. doi: 10.1053/j.ackd.2012.06.002.
10
Genetics of hyperuricemia and gout: implications for the present and future.
Curr Rheumatol Rep. 2013 Feb;15(2):309. doi: 10.1007/s11926-012-0309-8.
本文引用的文献
1
Effect of uric acid reduction on chronic kidney disease. Systematic review and meta-analysis.
Front Pharmacol. 2024 Mar 26;15:1373258. doi: 10.3389/fphar.2024.1373258. eCollection 2024.
2
Plasma and Urinary Metabolomic Analysis of Gout and Asymptomatic Hyperuricemia and Profiling of Potential Biomarkers: A Pilot Study.
Biomedicines. 2024 Jan 27;12(2):300. doi: 10.3390/biomedicines12020300.
3
Dysuricemia.
Biomedicines. 2023 Nov 28;11(12):3169. doi: 10.3390/biomedicines11123169.
4
The Association of Smoking and Hyperuricemia with Renal Arteriolosclerosis in IgA Nephropathy.
Biomedicines. 2023 Jul 21;11(7):2053. doi: 10.3390/biomedicines11072053.
5
A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases.
Biomedicines. 2023 May 14;11(5):1445. doi: 10.3390/biomedicines11051445.
6
Impact of Hyper- and Hypo-Uricemia on Kidney Function.
Biomedicines. 2023 Apr 24;11(5):1258. doi: 10.3390/biomedicines11051258.
7
Dysuricemia-A New Concept Encompassing Hyperuricemia and Hypouricemia.
Biomedicines. 2023 Apr 23;11(5):1255. doi: 10.3390/biomedicines11051255.
8
Inflammation Related to Association of Low Uric Acid and Progression to Severe Disease in Patients Hospitalized for Non-Severe Coronavirus Disease 2019.
Biomedicines. 2023 Mar 10;11(3):854. doi: 10.3390/biomedicines11030854.
9
Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study.
Biomedicines. 2023 Mar 1;11(3):754. doi: 10.3390/biomedicines11030754.
10
The Effects of Topiroxostat, a Selective Xanthine Oxidoreductase Inhibitor, on Arterial Stiffness in Hyperuricemic Patients with Liver Dysfunction: A Sub-Analysis of the BEYOND-UA Study.
Biomedicines. 2023 Feb 23;11(3):674. doi: 10.3390/biomedicines11030674.
Zotero 插件